Janux Therapeutics (NASDAQ:JANX) Price Target Lowered to $26.00 at Piper Sandler

Janux Therapeutics (NASDAQ:JANX) had its target price lowered by Piper Sandler from $30.00 to $26.00 in a research note issued to investors on Friday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other equities research analysts also recently issued reports on JANX. Barclays downgraded shares of Janux Therapeutics from an “overweight” rating to an “underweight” rating and reduced their price objective for the stock from $29.00 to $14.00 in a research note on Monday, April 20th. Weiss Ratings raised shares of Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 22nd. Cantor Fitzgerald reduced their price target on shares of Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Wedbush decreased their price objective on shares of Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday. Finally, Truist Financial raised Janux Therapeutics to a “strong-buy” rating in a report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.83.

Janux Therapeutics Trading Down 2.5%

NASDAQ JANX opened at $14.18 on Friday. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34. The company has a 50 day moving average of $14.35 and a 200-day moving average of $17.45. The company has a market cap of $864.41 million, a price-to-earnings ratio of -7.71 and a beta of 2.58.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.13. The company had revenue of $3.73 million during the quarter, compared to analyst estimates of $4.36 million. On average, equities research analysts forecast that Janux Therapeutics will post -2.34 earnings per share for the current year.

Institutional Trading of Janux Therapeutics

A number of hedge funds have recently made changes to their positions in JANX. AQR Capital Management LLC grew its holdings in shares of Janux Therapeutics by 71.7% during the first quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock worth $262,000 after purchasing an additional 4,059 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Janux Therapeutics by 18.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company’s stock valued at $583,000 after buying an additional 3,393 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Janux Therapeutics by 12.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company’s stock valued at $5,033,000 after buying an additional 20,657 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Janux Therapeutics by 82.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 247,424 shares of the company’s stock worth $5,715,000 after buying an additional 112,116 shares during the period. Finally, Legal & General Group Plc boosted its position in Janux Therapeutics by 12.0% during the 2nd quarter. Legal & General Group Plc now owns 47,353 shares of the company’s stock worth $1,094,000 after buying an additional 5,055 shares during the period. 75.39% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: The company reported a smaller-than-expected quarterly loss of $0.39 per share, beating estimates of a $0.52 loss, which may help support investor sentiment. Press Release
• Neutral Sentiment: Revenue came in at $3.73 million, below analyst expectations of $4.36 million, offsetting some of the earnings beat and limiting the immediate upside reaction.
• Neutral Sentiment: Guggenheim lowered its price target to $58 from $68 but maintained a Buy rating, signaling continued long-term confidence despite trimming expectations.
• Neutral Sentiment: Wedbush cut its target to $36 from $45 and kept an Outperform rating, indicating analysts still see meaningful upside but are becoming more cautious.
• Negative Sentiment: Piper Sandler reduced its target to $26 from $30, though it maintained an Overweight rating, adding to the theme of lower near-term valuation expectations.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.